Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 165

  • Filters activated: AIDS. Clear all to show 3118 items.
  • The following term was not found in PubMed: 135968-09-1[rn].
1.

Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.

Herr MM, Torka P, Zhang Y, Wallace PK, Tario JD Jr, Repasky EA, Chen GL, Ho CM, Balderman SR, Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T.

Bone Marrow Transplant. 2019 Jun 21. doi: 10.1038/s41409-019-0591-4. [Epub ahead of print]

PMID:
31227776
2.

The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation.

Couban S, Wong PC, Schultz KR.

Exp Hematol. 2019 Feb;70:1-9. doi: 10.1016/j.exphem.2018.11.003. Epub 2018 Nov 11. Review.

PMID:
30428338
3.

Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.

Matsue K, Kumagai K, Sugiura I, Ishikawa T, Igarashi T, Sato T, Uchiyama M, Miyamoto T, Ono T, Ueda Y, Kiguchi T, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2018 Nov;108(5):524-534. doi: 10.1007/s12185-018-2505-4. Epub 2018 Jul 24. Erratum in: Int J Hematol. 2018 Aug 30;:.

PMID:
30043330
4.

A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.

Mai NT, Dobbs N, Phu NH, Colas RA, Thao LT, Thuong NT, Nghia HD, Hanh NH, Hang NT, Heemskerk AD, Day JN, Ly L, Thu DD, Merson L, Kestelyn E, Wolbers M, Geskus R, Summers D, Chau NV, Dalli J, Thwaites GE.

Elife. 2018 Feb 27;7. pii: e33478. doi: 10.7554/eLife.33478.

5.

CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.

Kariminia A, Ivison S, Ng B, Rozmus J, Sung S, Varshney A, Aljurf M, Lachance S, Walker I, Toze C, Lipton J, Lee SJ, Szer J, Doocey R, Lewis I, Smith C, Chaudhri N, Levings MK, Broady R, Devins G, Szwajcer D, Foley R, Mostafavi S, Pavletic S, Wall DA, Couban S, Panzarella T, Schultz KR.

Haematologica. 2017 Nov;102(11):1936-1946. doi: 10.3324/haematol.2017.170928. Epub 2017 Sep 21.

6.

Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.

Partanen A, Valtola J, Ropponen A, Vasala K, Penttilä K, Ågren L, Pyörälä M, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E.

Ann Hematol. 2017 Nov;96(11):1897-1906. doi: 10.1007/s00277-017-3123-6. Epub 2017 Sep 7.

PMID:
28879595
7.

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2065-2069. doi: 10.1016/j.bbmt.2017.07.023. Epub 2017 Aug 7.

8.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.

Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation).

Am J Hematol. 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. No abstract available.

9.
10.

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.

Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K.

Int J Hematol. 2017 Oct;106(4):562-572. doi: 10.1007/s12185-017-2255-8. Epub 2017 May 19.

PMID:
28527129
11.

Dexamethasone promotes granulocyte mobilization by prolonging the half-life of granulocyte-colony-stimulating factor in healthy donors for granulocyte transfusions.

Hiemstra IH, van Hamme JL, Janssen MH, van den Berg TK, Kuijpers TW.

Transfusion. 2017 Mar;57(3):674-684. doi: 10.1111/trf.13941. Epub 2016 Dec 28.

PMID:
28032635
12.

Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).

Aapro M, Bokemeyer C, Ludwig H, Gascón P, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, MacDonald K, Abraham I.

J Geriatr Oncol. 2017 Mar;8(2):86-95. doi: 10.1016/j.jgo.2016.09.006. Epub 2016 Nov 6.

14.

Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.

Teusink A, Pinkard S, Davies S, Mueller M, Jodele S.

Transfusion. 2016 Jun;56(6):1402-5. doi: 10.1111/trf.13599. Epub 2016 Apr 15.

PMID:
27079854
15.

Tbo-Filgrastim: A Review in Neutropenic Conditions.

Blair HA, Scott LJ.

BioDrugs. 2016 Apr;30(2):153-60. doi: 10.1007/s40259-016-0172-7. Review.

PMID:
27023705
16.

Good's Syndrome: Successful Management of Thymoma With Hypoimmunoglobulinemia.

DeBoard ZM, Taylor BJ.

Ann Thorac Surg. 2015 Nov;100(5):1903-5. doi: 10.1016/j.athoracsur.2014.12.108.

PMID:
26522540
17.

Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.

Marciano S, Galdame OA, Barcan LA, Gadano AC.

Acta Gastroenterol Latinoam. 2015 Mar;45(1):76-9.

PMID:
26076519
18.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024. Epub 2015 May 30.

19.

Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.

Gattillo S, Marktel S, Rizzo L, Malato S, Malabarba L, Coppola M, Assanelli A, Milani R, De Freitas T, Corti C, Bellio L, Ciceri F.

Transfusion. 2015 Aug;55(8):1993-2000. doi: 10.1111/trf.13059. Epub 2015 Feb 26.

PMID:
25721167

Supplemental Content

Loading ...
Support Center